FDA Severe-Bleeding Workshop Addresses Need For Effective Local Agents
This article was originally published in The Gray Sheet
Panelists at a recent FDA workshop on severe bleeding said there is a need for effective local agents to treat severe bleeding in trauma and surgical cases, and explored a set of primary clinical endpoints for studying the products in rigorous trials.
You may also be interested in...
Recent debuts and approvals include Covidien’s AS Meniscal repair device, Medtronic’s Sentrino continuous glucose management system and Blue Belt’s NavioPFS system for partial knee replacement.
Genzyme unloads Dx unit
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.